Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $14.12 in the prior trading day, Myriad Genetics, Inc (NASDAQ: MYGN) closed at $13.82, down -2.12%. In other words, the price has decreased by -$2.12 from its previous closing price. On the day, 0.65 million shares were traded. MYGN stock price reached its highest trading level at $14.3 during the session, while it also had its lowest trading level at $13.78.
Ratios:
Our goal is to gain a better understanding of MYGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on December 10, 2024, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 09, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $30 to $21.
On September 19, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $32.Morgan Stanley initiated its Equal-Weight rating on September 19, 2024, with a $32 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1258106496 and an Enterprise Value of 1301306880. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.53 while its Price-to-Book (P/B) ratio in mrq is 1.72. Its current Enterprise Value per Revenue stands at 1.58 whereas that against EBITDA is -38.387.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $13.92. The 50-Day Moving Average of the stock is -25.41%, while the 200-Day Moving Average is calculated to be -39.51%.
Shares Statistics:
The stock has traded on average 862.43K shares per day over the past 3-months and 1083750 shares per day over the last 10 days, according to various share statistics. A total of 91.00M shares are outstanding, with a floating share count of 87.62M. Insiders hold about 3.75% of the company’s shares, while institutions hold 100.22% stake in the company. Shares short for MYGN as of 1732838400 were 3390040 with a Short Ratio of 3.93, compared to 1730332800 on 4482742. Therefore, it implies a Short% of Shares Outstanding of 3390040 and a Short% of Float of 5.21.
